ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

fluticasone furoate

Also written as “GW685698X”, “FF/UMEC/VI” and “Fluticasone furoate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic, led by 4 companies.

Drug pageFluticasone furoate: every studyAll 105 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Feb 14, 200797 company-led studies, 2 open or runningNext primary completion: Jan 26, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only942 open or runningphase 4since Feb 14, 2007Feb 8, 2005Jan 26, 2027phase 3 · NCT05757102
Novartisits history only10 open or runningphase 3since Jan 17, 2011Jan 17, 2011none ahead
ORAits history only10 open or runningphase 4since Feb 24, 2010Feb 24, 2010none ahead
Sandoz10 open or runningphase 3since Oct 15, 2025Oct 15, 2025none ahead

Also a collaborator on its studies: Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sandoz only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2025First study: phase 3 study in RespiratoryFirst studyNCT07223294

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor agonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45
relacorilantruleCorcept Therapeuticsphase 322
Triamcinolone Acetonideruleclearside-biomedical-incphase 320

Studies

The one study Sandoz leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07223294Respiratory3WithdrawnApr 21, 20260

How it is read

Names in the registry

  • “GW685698X”, 16 entries
  • “FF/UMEC/VI”, 9 entries
  • “Fluticasone furoate”, 8 entries
  • “FF”, 6 entries
  • “Fluticasone Furoate”, 5 entries

Codes read as this program: GW685698.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.